Wen-Jen Hwu - Concepedia

Author

Wen-Jen Hwu

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Patrick Hwu, W. Hwu, W. J. Hwu, W.-J. Hwu, Wen-Jen Hwu

Publications

30.3K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Melanoma Institute Australia Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Merck & Co., Inc., Rahway, NJ, USA (United States)

About

Wen-Jen Hwu is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	32	9.3K
2	Health Sciences	3	3	503
3	Allergy	2	2	115
4	Social Sciences	1	1	107
5	Biochemistry	1	1	107

Wen-Jen Hwu

Publications

30.1K

Citations

H-Index

Page 1

	Year	Citations
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, New England Journal of Medicine	2012	7.9K
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients Vancheswaran Gopalakrishnan, Christine N. Spencer, Luigi Nezi, Science	2017	4.4K
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid, Caroline Robert, Adil Daud, New England Journal of Medicine	2013	3.4K
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov, Cell Microenvironment EvolutionTumor ImmunologyCancer ImmunosurveillanceImmunologyImmune Checkpoint Inhibitor	2017	2.5K
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Caroline Robert, Antoni Ribas, Jedd D. Wolchok, The Lancet OncologyMedicineIpilimumab-refractory Advanced MelanomaImmunologyMelanoma	2014	1.7K
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Antoni Ribas, Omid Hamid, Adil Daud, JAMA	2016	1K
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade Pei-Ling Chen, Whijae Roh, Alexandre Reuben, Cancer Discovery	2016	971
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance Whijae Roh, Pei-Ling Chen, Alexandre Reuben, Science Translational Medicine T-regulatory CellImmunologyPathologyImmune Checkpoint BlockadeImmunotherapy	2017	902
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma Rodabe N. Amaria, Sangeetha M. Reddy, Hussein A. Tawbi, Nature Medicine MedicineMelanomaImmunologyTumor ImmunityImmune Checkpoint Inhibitor	2018	797
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Journal of Clinical Oncology	2016	742

Page 1